Home > Healthcare > Healthcare IT > Payer/Provider Solutions > Digital Psychotherapeutics Market

Digital Psychotherapeutics Market Share

Report ID: GMI7175
Published Date: Oct 2023
Report Format: PDF

Download Free Sample

Digital Psychotherapeutics Market Share

The digital psychotherapeutics industry is fragmented in nature, with a large number of small and medium-sized companies competing with each other. However, there are a few larger companies that are focusing on improving their market share. Prominent players such as Pear Therapeutics, SilverCloud Health, and Woebot Health hold a notable share in the market. These companies are diligently directing their efforts towards continuous solution innovation to gain substantial market share.

Some of the eminent market participants operating in the digital psychotherapeutics industry include:

Novartis AG
Pear Therapeutics
SilverCloud Health
Woebot Health
Starling Minds
SwissDT
AbleTo, Inc.
Spring Care, Inc
Meru
Ginger

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Digital psychotherapeutics industry reached around USD 1.2 billion in revenue in 2022 and is projected to be worth USD 16.9 billion by 2032 owing to the rising prevalence of psychological disorders and the surging demand for accessible and effective treatment choices.

The combination therapy segment generated USD 836 million in 2022 and is estimated to witness high demand through 2032 attributed to its improved treatment efficacy.

North America digital psychotherapeutics industry amassed USD 700.3 million in revenue in 2022 and is set to witness robust growth through 2032 with the increasing mental health awareness and the growing recognition of the importance of mental well-being in the region.

The competitive landscape of the digital psychotherapeutics industry includes prominent firms, such as Novartis AG, Pear Therapeutics, SilverCloud Health, Woebot Health, Starling Minds, SwissDT, AbleTo, Inc., Spring Care, Inc, Meru, and Ginger.